Literature DB >> 11594935

von Economo encephalitis.

M S Dickman1.   

Abstract

In April 1917, Dr Constantin von Economo presented his clinical and pathologic findings of a new disease--soon to be part of a worldwide epidemic--before the Vienna Psychiatric Society. He named it encephalitis lethargica. After years of careful observation, he collected and analyzed thousands of cases and classified them into 3 clinical syndromes: somnolent-ophthalmoplegic, hyperkinetic, and amyostatic-akinetic forms. He described the now legendary postencephalitic Parkinsonism, noting that symptoms could emerge years after the original infection, often without signs of prodromal "flu." He emphasized the neuropathologic findings: inflammatory changes in the tegmentum of the midbrain accounting for the sleep disturbance and ocular signs. After encountering sporadic cases following the epidemic, he concluded that the somnolent-ophthalmoplegic syndrome was the primary expression of encephalitis lethargica. This article outlines the observations and conclusions of Dr von Economo during and after the epidemic through seminal quotations primarily from his published works, as well as from more recent reports.

Entities:  

Mesh:

Year:  2001        PMID: 11594935     DOI: 10.1001/archneur.58.10.1696

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  17 in total

1.  Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice.

Authors:  Haeman Jang; David Boltz; Jennifer McClaren; Amar K Pani; Michelle Smeyne; Ane Korff; Robert Webster; Richard Jay Smeyne
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

2.  The Insomnia Plague in Fictional Macondo.

Authors:  Alejandro Velásquez-Torres; Andrés Díaz-Forero; Claudia Talero-Gutiérrez
Journal:  Perm J       Date:  2020

3.  Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia-A Mixed Method Prospective Cohort and Nested Case-Control Study: Study Protocol.

Authors:  Rosalia Dacosta-Aguayo; Noemí Lamonja-Vicente; Carla Chacón; Lucia Amalía Carrasco-Ribelles; Pilar Montero-Alia; Anna Costa-Garrido; Rosa García-Sierra; Victor M López-Lifante; Eduard Moreno-Gabriel; Marta Massanella; Josep Puig; Jose A Muñoz-Moreno; Lourdes Mateu; Anna Prats; Carmina Rodríguez; Maria Mataró; Julia G Prado; Eva Martínez-Cáceres; Concepción Violán; Pere Torán-Monserrat
Journal:  Vaccines (Basel)       Date:  2022-05-26

4.  Influenza-associated global amnesia and hippocampal imaging abnormality.

Authors:  Jonathan Lopez; Catherine Lomen-Hoerth; Gayle K Deutsch; Geoffrey A Kerchner; Anita Koshy
Journal:  Neurocase       Date:  2013-05-22       Impact factor: 0.881

5.  Infection triggers symptoms similar to those of Parkinson's disease in mice lacking PINK1 protein.

Authors:  Mary K Herrick; Malú G Tansey
Journal:  Nature       Date:  2019-07       Impact factor: 49.962

Review 6.  A Practical Approach to Early-Onset Parkinsonism.

Authors:  Giulietta M Riboldi; Emanuele Frattini; Edoardo Monfrini; Steven J Frucht; Alessio Di Fonzo
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

7.  Viral-toxin interactions and Parkinson's disease: poly I:C priming enhanced the neurodegenerative effects of paraquat.

Authors:  Jessica Bobyn; Emily N Mangano; Anusha Gandhi; Eric Nelson; Kerry Moloney; Melanie Clarke; Shawn Hayley
Journal:  J Neuroinflammation       Date:  2012-05-04       Impact factor: 8.322

8.  Brain and aviation: on the 80th anniversary of Constantin von Economo's (1876-1931) death.

Authors:  Jarosław Sak; Andrzej Grzybowski
Journal:  Neurol Sci       Date:  2012-05-09       Impact factor: 3.307

9.  The Demise of Poskanzer and Schwab's Influenza Theory on the Pathogenesis of Parkinson's Disease.

Authors:  Danny Estupinan; Sunina Nathoo; Michael S Okun
Journal:  Parkinsons Dis       Date:  2013-06-11

Review 10.  Nonrespiratory sites of influenza-associated disease: mechanisms and experimental systems for continued study.

Authors:  Heather M Froggatt; Nicholas S Heaton
Journal:  FEBS J       Date:  2022-02-07       Impact factor: 5.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.